CRSP CRISPR Therapeutics AG

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRSP

Price (delayed)

$45

Market cap

$3.54B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.36

Enterprise value

$3.56B

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that ...

Highlights
The company's net income rose by 4.5% QoQ
The EPS is up by 5% since the previous quarter
CRSP's quick ratio is down by 25% YoY but it is up by 19% QoQ
The company's gross profit has shrunk by 100% YoY and by 91% QoQ
The revenue has dropped by 100% year-on-year and by 91% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://crisprtx.com
Peers: OVID

Key stats

What are the main financial stats of CRSP
Market
Shares outstanding
78.65M
Market cap
$3.54B
Enterprise value
$3.56B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.88
Price to sales (P/S)
2,920.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,971.29
Earnings
Revenue
$1.2M
EBIT
-$650.5M
EBITDA
-$626.33M
Free cash flow
-$532.93M
Per share
EPS
-$8.36
Free cash flow per share
-$6.85
Book value per share
$23.95
Revenue per share
$0.02
TBVPS
$28.85
Balance sheet
Total assets
$2.24B
Total liabilities
$367.58M
Debt
$244.02M
Equity
$1.88B
Working capital
$1.73B
Liquidity
Debt to equity
0.13
Current ratio
15.3
Quick ratio
15.09
Net debt/EBITDA
-0.03
Margins
EBITDA margin
-52,281.1%
Gross margin
100%
Net margin
-54,271.7%
Operating margin
-56,190.4%
Efficiency
Return on assets
-26.9%
Return on equity
-31.9%
Return on invested capital
-31.8%
Return on capital employed
-30.7%
Return on sales
-54,298.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRSP stock price

How has the CRISPR Therapeutics AG stock price performed over time
Intraday
-0.13%
1 week
0.18%
1 month
-10.68%
1 year
-33.33%
YTD
10.7%
QTD
10.7%

Financial performance

How have CRISPR Therapeutics AG's revenue and profit performed over time
Revenue
$1.2M
Gross profit
$1.2M
Operating income
-$673.16M
Net income
-$650.18M
Gross margin
100%
Net margin
-54,271.7%
The company's gross profit has shrunk by 100% YoY and by 91% QoQ
The revenue has dropped by 100% year-on-year and by 91% since the previous quarter
The company's net income rose by 4.5% QoQ
The company's operating income rose by 2.1% QoQ

Growth

What is CRISPR Therapeutics AG's growth rate over time

Valuation

What is CRISPR Therapeutics AG stock price valuation
P/E
N/A
P/B
1.88
P/S
2,920.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,971.29
The EPS is up by 5% since the previous quarter
The price to book (P/B) is 57% lower than the 5-year quarterly average of 4.4 and 15% lower than the last 4 quarters average of 2.2
The equity has decreased by 22% YoY and by 4% QoQ
The price to sales (P/S) is 100% higher than the 5-year quarterly average of 1461.3
The revenue has dropped by 100% year-on-year and by 91% since the previous quarter

Efficiency

How efficient is CRISPR Therapeutics AG business performance
The ROIC rose by 6% QoQ

Dividends

What is CRSP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRSP.

Financial health

How did CRISPR Therapeutics AG financials performed over time
CRSP's quick ratio is down by 25% YoY but it is up by 19% QoQ
CRISPR Therapeutics AG's current ratio has decreased by 24% YoY but it has increased by 19% from the previous quarter
The debt is 87% smaller than the equity
CRSP's debt to equity is up by 44% YoY and by 8% QoQ
The equity has decreased by 22% YoY and by 4% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.